Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Ricotta

Vascular Surgery Delray Beach, FL Medical Doctor

NPI 1407824097 CMS profile 199184

16215 S Jog Rd Ste 100, Delray Beach, FL 33446

Open in the dashboard

General payments

$155,837

713 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$188,633 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Joseph Ricotta of Delray Beach, FL is reported in the CMS Open Payments database as having received $155,837 across 713 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $188,633 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50,922 95
2024 General $20,076 108
2023 General $46,387 123
2022 General $13,128 135
2021 General $9,754 99
2020 General $6,391 54
2019 General $9,178 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Ricotta
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Joseph Ricotta were reported at $50,922. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Joseph Ricotta Vascular Surgery median Middle half National median
2019 $9,178 $796 $226–$2,363 $163
2020 $6,391 $348 $118–$1,110 $114
2021 $9,754 $471 $158–$1,421 $132
2022 $13,128 $725 $222–$2,183 $149
2023 $46,387 $836 $257–$2,440 $160
2024 $20,076 $909 $252–$2,619 $164
2025 $50,922 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Philips Electronics North America Corporation $35,849 80 payments
  2. Boston Scientific Corporation $35,079 63 payments
  3. Silk Road Medical, Inc. $33,547 68 payments
  4. Medtronic, Inc. $28,134 63 payments
  5. Medtronic Vascular, Inc. $8,751 28 payments
  6. Endologix, Inc. $2,710 10 payments
  7. W. L. Gore & Associates, Inc. $1,796 44 payments
  8. Abbott Laboratories $1,270 19 payments
  9. Penumbra, Inc. $1,270 51 payments
  10. Cardiovascular Systems Inc. $1,224 60 payments
  11. Other $6,207 227 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $42,990 16 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,995 13 payments
  3. Honoraria $26,325 4 payments
  4. Grant $25,000 2 payments
  5. Food and Beverage $20,763 668 payments
  6. Gift $2,995 1 payment
  7. Travel and Lodging $1,567 5 payments
  8. Education $202 4 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Stent $33,189 60 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $33,189 60 payments
  3. (6554) Periph Vasc Undiv $26,368 6 payments
  4. ENROUTE Transcarotid Neuroprotection System Enroute Nps Angle US - Pi $18,905 5 payments
  5. ENDURANT IIS $10,415 24 payments
  6. ENROUTE Transcarotid Neuroprotection System Enroute Nps 2.5 Plus - Pi $7,637 4 payments
  7. ENROUTE Transcarotid Neuroprotection System Cardiology Vascular Diseases $6,386 3 payments
  8. (6554) Peripheral Vascular Undivided $4,898 3 payments
  9. VenaSeal $4,846 5 payments
  10. ENHANCE Transcarotid Peripheral Access Kit $4,142 13 payments
  11. Other $37,807 711 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

1,137

Median for Vascular Surgery: 122

Drug cost

$80,813

Median for Vascular Surgery: $14,135

Branded share of claims

77.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 103 $51,846
Eliquis Apixaban Brand 23 $16,327
Xarelto Rivaroxaban Brand 12 $7,716
Clopidogrel Clopidogrel Bisulfate Brand 307 $2,754
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 433 $1,782
Cephalexin Generic 155 $222
Tramadol Hcl Generic 53 $99
Doxycycline Hyclate Generic 36 $58
Diazepam Generic 15 $9

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 146 billing codes

Paid by Medicare

$4,669,791

Medicare's payments for the services billed

Medicare patients

2,175

Average age 79

Services billed

14,351

1,125 women, 1,050 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 60%
Chronic kidney disease 45%
Diabetes 40%
Atrial fibrillation 34%
Depression 32%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

713 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record